This is a working overview of gastric juice protein, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-11. Anything still debated is marked as such rather than presented as settled.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
=== In apricot === Apricot as a climacteric fruit undergoes fast post-harvest maturation. The latent PPO form can spontaneously activate during the first weeks of storage, generating the active enzyme with a molecular weight of 38 kDa. Ascorbic acid/protease combinations constitute a promising practical anti-browning method as treated apricot purees preserved their color.
III (stylized as (III)) is the third studio album by Canadian electronic music duo Crystal Castles, released on November 7, 2012, by Fiction Records and Polydor Records. Production was handled by Ethan Kath, with additional production by Jacknife Lee. III is the last Crystal Castles album with vocalist Alice Glass before her departure in 2014, and is also their last eponymous album, as the band's 2016 album is titled Amnesty (I) instead of (IV) or Crystal Castles. Glass continued the series on her own by including "IV" into the title of her 2022 debut album Prey//IV.
Mariusz Zbigniew Pudzianowski (Polish pronunciation: [ˈmarjuʂ pudʑaˈnɔfskʲi]; born 7 February 1977), also known as 'Pudzian' and 'Dominator', is a Polish former strongman and mixed martial artist. With 43 international titles at a record 70% win percentage, 58 total wins, 71 podiums and 28 world records in his strongman career. During his career as a strongman, Pudzianowski won five World's Strongest Man titles in 2002, 2003, 2005, 2007 and 2008, the most in the 48 year history of the competition. He also won two runner-up titles in 2006 and 2009 and made 9 out of 9 appearances into the World's Strongest Man final (a feat replicated only by Hafþór Júlíus Björnsson since then). While securing eight World Strongman Cup Federation wins and twelve Strongman Super Series wins, he also won the Europe's Strongest Man title a record six times and the Poland's Strongest Man title a record seven times. In 2009, Pudzianowski started his career as a mixed martial artist. By 2022, he had won his 17th professional fight.
== Malignant neoplasm of digestive organs and peritoneum (150–159) == 150 Malignant neoplasm of esophagus 151 Malignant neoplasm of stomach 152 Malignant neoplasm of small intestine, including duodenum 153 Malignant neoplasm colon 154 Malignant neoplasm of rectum, rectosigmoid junction, and anus 155 Malignant neoplasm of liver and intrahepatic bile ducts 156 Malignant neoplasm of gallbladder and extrahepatic bile ducts 157 Malignant neoplasm of pancreas 158 Malignant neoplasm of retroperitoneum and peritoneum 159 Malignant neoplasm of other and ill-defined sites within the
Sources: en.wikipedia.org
The new 32nd district covers several suburban areas directly north and northeast of Dallas, including most of the Dallas County portion of Carrollton and Addison along with all of Richardson (including the Collin County portion) and the northern halves of Garland and Rowlett, as well as the far north side of Dallas itself. The district then stretches eastward and crosses Lake Ray Hubbard to take in suburban Rockwall County and the Lake Tawakoni area, traveling all the way east to such northern Tyler exurbs as Mineola and Gilmer. Prior to redistricting, the incumbent was Democrat Julie Johnson; however, Johnson was drawn out of the 32nd district and into the 24th, ultimately deciding to seek reelection in the 33rd district (see below) and leaving this district as an open seat. In 2024, the new district gave 57.7% of the vote to Donald Trump and 55.2% to Ted Cruz, with Democrats only considered competitive in the Dallas County and Richardson portion of the otherwise heavily Republican district.
== History == Brucella canis was first discovered in the United States by Leland Carmichael in 1966, when the bacterium was identified in canine vaginal discharge and the tissues from mass abortions in beagles. B. canis was said to be a biovar of B. suis. With recent research, PCR assay data was able to contradict B. canis and B. suis. PCR data showed a complete difference between the two strains along with B. suis biovars unattained from B. canis DNA. PCR assays have been proven beneficial when differentiating between Brucella strains and vaccine strains. Investigations into the bacterium revealed that domestic dogs are primarily affected along with other canine species. B. canis causes reproductive issues in female dogs, usually in the form of late-term spontaneous abortions. While in males, epididymitis, orchitis, and infertility were observed due to the bacterium. During the 1970s and 1980s, B. canis was reported in North America, Europe, and Asia. The reports were mainly from commercial breeding kennels wherein the bacterium can easily spread. Increase in infections were also attributed to the growing adoption of dogs as pets. By the 2000s, molecular analysis revealed that B. canis is unique from other Brucella species, categorized as a naturally occurring rough species that needs an anti-rough lipopolysaccharide reagent for detection. B. canis has been recognized as a growing zoonotic risk worldwide, having the ability to infect humans. Laboratory exposure or contact with pet dogs that had aborted fetuses were the main sources of exposure to the bacterium.
The double membrane sheets are stacked and connected through several right- or left-handed helical ramps, the "Terasaki ramps", giving rise to a structure resembling a parking garage. Although there is no continuous membrane between the endoplasmic reticulum and the Golgi apparatus, membrane-bound transport vesicles shuttle proteins between these two compartments. Vesicles are surrounded by coating proteins called COPI and COPII. COPII targets vesicles to the Golgi apparatus and COPI marks them to be brought back to the rough endoplasmic reticulum. The rough endoplasmic reticulum works in concert with the Golgi complex to target new proteins to their proper destinations. The second method of transport out of the endoplasmic reticulum involves areas called membrane contact sites, where the membranes of the endoplasmic reticulum and other organelles are held closely together, allowing the transfer of lipids and other small molecules. The rough endoplasmic reticulum is key in multiple functions:
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.